HOME2019-03-11T17:27:49+00:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

Read the latest PD-MitoQUANT-acknowledged publication co-authored by our PIs at CNRS

January 20th, 2020|

Congratulations to all authors involved in the latest PD-MitoQUANT-acknowledged publication: Nolwen L. Rey, Luc Bousset, Sonia George, Zachary Madaj, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Ronald Melki and Patrik Brundin. PD-MitoQUANT PIs Luc Bousset and Ronald Melki are researchers at the Centre National de la Recherche Scientifique (CNRS). The [...]

Interview with PI Dr Olga Corti, ICM

December 20th, 2019|

Olga Corti, PhD is a Research Director at the Institut du Cerveau et de la Moelle épinière (ICM) located in Paris, France. Olga is an expert in the functional analysis of protein products of Parkinson’s genes with a focus on mechanisms of mitochondrial quality control. We asked Olga some [...]

Read more